|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||324.71 - 333.28|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.74|
|PE Ratio (TTM)||15.42|
|Earnings Date||Apr 22, 2019 - Apr 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||385.63|
Announcement: Moody's announces completion of a periodic review of ratings of Biogen Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its Phase 3 clinical trial. This gave a possible opening to Viking Therapeutics, which gave a boost to VKTX stock.Source: Shutterstock Does that make it a buy? Let's examine the stock a bit more closely. If you haven't heard of VKTX stock before, don't feel guilty. With a market cap of just $650 million, it's not a well-known company. It's not a Bristol-Myers Squibb (NYSE:BMY), Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB) or another large cap biotech company. Breaking Down VKTX StockViking Therapeutics is a self-described "clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders." The company is working on several treatments, one of which includes enrolling VK2809, which is aimed at fatty liver and hypercholesterolemia, in a Phase 2 study. Gilead's Selonsertib liver treatment failed its Phase 3 clinical trial earlier this week, thus giving some hope to VKTX stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The company also has VK5211, "an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation."At the end of the day, Viking Therapeutics has some intriguing developments in its pipeline. But at the same time, this is also a speculative biotech company. Investors are, to some degree, betting on a binary event. Either VKTX stock is a multi-bagger with big-time potential if it gains regulatory approval and/or is acquired by a larger company, or neither of those things happen and it's a total dud. That's the nature of the beast with young biotech stocks.Case in point? Viking Therapeutics stock doesn't have any revenue. Its pipeline is promising, but that's all investors are betting on at this point. There's no real way to evaluate the business because there is no business! At least in the traditional sense. VKTX has enough money in the bank to fund its operations for the time being, but its future hinges solely on its treatments. Trading VKTX StockHopefully the chart above doesn't seem too complex. I only wanted to lay out a few different levels and prior trends that played a role in VKTX stock over the last 12 months.Like most of the market, VKTX came into Q4 near its highs, although admittedly under some pressure already. Still, the stock was pummeled along with the S&P 500 and other major market indices as Q4 got under way. VKTX stock price bottomed near $7 on Christmas Eve and has been working higher since.VKTX stock is now over the 50-day and 21-day moving averages. For traders and investors that are going in on this, perhaps consider using a $7 as a key reference level. Below this mark and Viking Therapeutics stock could be in trouble.As much as I want to say that the stock is okay over uptrend support (purple line) and moving average support -- and really, it is -- know that this is a speculative position that is subject to extreme moves in both directions. These moves can appear overnight and there's little investors can do about it other than planning ahead with proper position sizing. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? For those that don't want such a speculative position, consider choosing between two companies like Celgene and Gilead.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Should You Buy Viking Therapeutics After Gilead Drug Failure? appeared first on InvestorPlace.
The largest Insider Buys this week were for AT&T Inc. (NYSE:T), Biogen Inc. (BIIB), Abbott Laboratories (ABT) and Zimmer Biomet Holdings Inc. (ZBH). Warning! GuruFocus has detected 5 Warning Signs with T. Click here to check it out. AT&T Inc. an American multinational telecommunications conglomerate that is the second largest provider of mobile telephone services and the largest provider of fixed telephone services in the U.S. It also provides broadband subscription television services through DirecTV.
Biogen Inc NASDAQ/NGS:BIIBView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $15.64 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The decline was triggered by a Patent Trial and Appeal Board (PTAB) decision late Wednesday to consider Mylan NV’s challenge to a Biogen patent covering Biogen’s multiple sclerosis drug. The patent is critical in extending the medicine’s exclusivity into the next decade, and the PTAB’s ruling raises concerns about Tecfidera estimates, UBS analyst Carter Gould wrote in a note.
Biogen will likely prevail in a patent challenge from Mylan for its multiple sclerosis treatment Tecfidera, several analysts said this week, though Biogen stock stumbled in Thursday trades.
Mylan filled an inter partes review for Biogen's “514 patent,” the drug maker’s treatment patent on Tecfidera. The IPR was instituted on Wednesday.
Biogen Inc. shares declined in the extended session Wednesday after the U.S. Patent and Trademark Office said Mylan NV could likely succeed in a patent challenge to a Biogen multiple sclerosis drug. Biogen shares fell 2.8% after hours, following a 1.1% decline to close at $333.24. In a decision, the USPTO said that of 20 patent claims against Biogen's drug Tecfidera, Mylan "has demonstrated a reasonable likelihood that it will succeed on at least one of its challenges to patentability." On the other hand, shares of Mylan also declined, falling 1.5% after hours, following a 0.4% decline to close at $30.97.
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
Some insiders have made notable share purchases in the wake of earnings reports. Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Biogen Inc (NASDAQ: BIIB) saw a director step up to the buy window late last week.
Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. Knowing which valuation model to use for financial Read More...
The continued need for new Parkinson's disease treatments drew attention this week, with one local gene therapy biotech striking a $165 million collaboration deal, while another companies' drug was rejected by the FDA.
Biogen stock slipped Wednesday after Roche and AC Immune opted to scrap two Alzheimer's treatment studies — leading investors to look for details of Biogen's own experimental drug.
Shares of HCA Healthcare Inc. (HCA) jumped 4.78% to $138.03 on Tuesday after the Nashville, Tennessee-based medical care company beat analysts on both non-GAAP earnings per share by 44 cents and GAAP earnings per share by 41 cents for the last quarter of 2018. HCA Healthcare closed the trimester posting non-GAAP earnings per share of $2.99, representing a 131.5% increase from the prior-year quarter and GAAP earnings per share of $3.01, reflecting 130% growth year-over-year. Warning! GuruFocus has detected 3 Warning Sign with HCA.
Ionis Pharmaceuticals Inc (NASDAQ: IONS )'s partner Biogen Inc (NASDAQ: BIIB ) reported fourth-quarter results Wednesday before the market open, revealing that sales of the spinal muscular atrophy treatment ...
Big biotech stocks are having a bad day Wednesday, following muted guidance from (AMGN) (AMGN) and downbeat news about potential Alzheimer’s treatments from a rival of (BIIB) (BIIB). It’s a downbeat day for Amgen and Biogen, although that hasn’t hurt their smaller peers much. Amgen took a hit after reporting fourth-quarter earnings.